Karl F Mann

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3394953/publications.pdf

Version: 2024-02-01

			36303		32842
	117	10,695	51		100
	papers	citations	h-index		g-index
Ξ				. '	
	124	124	124		10005
	all docs	docs citations	times ranked		citing authors

#	Article	IF	CITATIONS
1	Examining a brief measure and observed cutoff scores to identify reward and relief drinking profiles: Psychometric properties and pharmacotherapy response. Drug and Alcohol Dependence, 2022, 232, 109257.	3.2	8
2	Association Between Functional and Structural Brain Connectivity of the Default Mode Network in Non-treatment Seeking Individuals With Alcohol Use Disorder. Alcohol and Alcoholism, 2022, 57, 540-551.	1.6	4
3	The effects of nalmefene on the impulsive and reflective system in alcohol use disorder: A resting-state fMRI study. Psychopharmacology, 2022, 239, 2471-2489.	3.1	2
4	Stability of Drinking Reductions and Long-term Functioning Among Patients with Alcohol Use Disorder. Journal of General Internal Medicine, 2021, 36, 404-412.	2.6	12
5	Reward drinking and naltrexone treatment response among young adult heavy drinkers. Addiction, 2021, 116, 2360-2371.	3 . 3	13
6	FMRI-based prediction of naltrexone response in alcohol use disorder: a replication study. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 915-927.	3.2	11
7	Nalmefene attenuates neural alcohol cue-reactivity in the ventral striatum and subjective alcohol craving in patients with alcohol use disorder. Psychopharmacology, 2021, 238, 2179-2189.	3.1	14
8	The World Health Organization Risk Drinking Levels Measure of Alcohol Consumption: Prevalence and Health Correlates in Nationally Representative Surveys of U.S. Adults, 2001–2002 and 2012–2013. American Journal of Psychiatry, 2021, 178, 548-559.	7.2	20
9	Genetic contributions to alcohol use disorder treatment outcomes: a genome-wide pharmacogenomics study. Neuropsychopharmacology, 2021, 46, 2132-2139.	5 . 4	19
10	Incubation of neural alcohol cue reactivity after withdrawal and its blockade by naltrexone. Addiction Biology, 2020, 25, e12717.	2.6	57
11	Safety of nalmefene for the treatment of alcohol use disorder: an update. Expert Opinion on Drug Safety, 2020, 19, 9-17.	2.4	3
12	"Who Am l―and "How Should I Be― a Systematic Review on Self-Concept and Avatar Identification in Gaming Disorder. Current Addiction Reports, 2020, 7, 166-193.	3.4	26
13	Reduction in World Health Organization Risk Drinking Levels and Cardiovascular Disease. Alcoholism: Clinical and Experimental Research, 2020, 44, 1625-1635.	2.4	17
14	World Health Organization risk drinking level reductions are associated with improved functioning and are sustained among patients with mild, moderate and severe alcohol dependence in clinical trials in the United States and United Kingdom. Addiction, 2020, 115, 1668-1680.	3.3	44
15	Which conditions should be considered as disorders in the International Classification of Diseases (ICD-11) designation of "other specified disorders due to addictive behaviors�. Journal of Behavioral Addictions, 2020, , .	3.7	165
16	Response to Dr. Mark Litt's Commentary. Alcoholism: Clinical and Experimental Research, 2019, 43, 2255-2256.	2.4	0
17	Efficacy of Short-term Treatment of Internet and Computer Game Addiction. JAMA Psychiatry, 2019, 76, 1018.	11.0	114
18	Advancing Precision Medicine for Alcohol Use Disorder: Replication and Extension of Reward Drinking as a Predictor of Naltrexone Response. Alcoholism: Clinical and Experimental Research, 2019, 43, 2395-2405.	2.4	44

#	Article	IF	CITATIONS
19	Reduction in non-abstinent World Health Organization (WHO) drinking risk levels and drug use disorders: 3-year follow-up results in the US general population. Drug and Alcohol Dependence, 2019, 201, 16-22.	3.2	19
20	Reduction in non-abstinent WHO drinking risk levels and depression/anxiety disorders: 3-year follow-up results in the US general population. Drug and Alcohol Dependence, 2019, 197, 228-235.	3.2	42
21	Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials. JAMA Psychiatry, 2019, 76, 374.	11.0	77
22	Maintenance of World Health Organization Risk Drinking Level Reductions and Posttreatment Functioning Following a Large Alcohol Use Disorder Clinical Trial. Alcoholism: Clinical and Experimental Research, 2019, 43, 979-987.	2.4	41
23	The effects of nalmefene on emotion processing in alcohol use disorder – A randomized, controlled fMRI study. European Neuropsychopharmacology, 2019, 29, 1442-1452.	0.7	14
24	Medication Development: Reducing Casualties in the Valley of Death and Providing Support for Survivors. Alcoholism: Clinical and Experimental Research, 2019, 43, 22-25.	2.4	1
25	The links between healthy, problematic, and addicted Internet use regarding comorbidities and self-concept-related characteristics. Journal of Behavioral Addictions, 2018, 7, 31-43.	3.7	64
26	Amygdala grey matter volume increase in gambling disorder with depression symptoms of clinical relevance: a voxel-based morphometry study. International Gambling Studies, 2018, 18, 259-268.	2.1	0
27	Global Scientific Production on Illicit Drug Addiction: A Two-Decade Analysis. European Addiction Research, 2018, 24, 60-70.	2.4	32
28	Precision Medicine in Alcohol Dependence: A Controlled Trial Testing Pharmacotherapy Response Among Reward and Relief Drinking Phenotypes. Neuropsychopharmacology, 2018, 43, 891-899.	5.4	91
29	Transancestral GWAS of alcohol dependence reveals common genetic underpinnings with psychiatric disorders. Nature Neuroscience, 2018, 21, 1656-1669.	14.8	490
30	Drinking Risk Level Reductions Associated with Improvements in Physical Health and Quality of Life Among Individuals with Alcohol Use Disorder. Alcoholism: Clinical and Experimental Research, 2018, 42, 2453-2465.	2.4	82
31	Reduction in Nonabstinent <scp>WHO</scp> Drinking Risk Levels and Change in Risk for Liver Disease and Positive <scp>AUDIT</scp> Scores: Prospective 3â€Year Followâ€Up Results in the <scp>U.S.</scp> General Population. Alcoholism: Clinical and Experimental Research, 2018, 42, 2256-2265.	2.4	43
32	Response to Letter to Editor (Precision medicine in alcohol dependence: evidence of efficacy and) Tj ETQq0 0 0 r	gBT /Over	lock 10 Tf 50
33	Efficacy and safety of sodium oxybate in alcoholâ€dependent patients with a very high drinking risk level. Addiction Biology, 2018, 23, 969-986.	2.6	59
34	Shared genetic etiology between alcohol dependence and major depressive disorder. Psychiatric Genetics, 2018, 28, 66-70.	1.1	19
35	Frontal cortex gray matter volume alterations in pathological gambling occur independently from substance use disorder. Addiction Biology, 2017, 22, 864-872.	2.6	38
36	Pathological gambling: a review of the neurobiological evidence relevant for its classification as an addictive disorder. Addiction Biology, 2017, 22, 885-897.	2.6	111

#	Article	IF	CITATIONS
37	Negative Association Between <scp>MR</scp> â€Spectroscopic Glutamate Markers and Gray Matter Volume After Alcohol Withdrawal in the Hippocampus: A Translational Study in Humans and Rats. Alcoholism: Clinical and Experimental Research, 2017, 41, 323-333.	2.4	23
38	Deep grey matter iron accumulation in alcohol use disorder. NeuroImage, 2017, 148, 115-122.	4.2	27
39	Temporal Stability of Heavy Drinking Days and Drinking Reductions Among Heavy Drinkers in the <scp>COMBINE</scp> Study. Alcoholism: Clinical and Experimental Research, 2017, 41, 1054-1062.	2.4	25
40	Blunted ventral striatal responses to anticipated rewards foreshadow problematic drug use in novelty-seeking adolescents. Nature Communications, 2017, 8, 14140.	12.8	87
41	The role of emotional inhibitory control in specific internet addiction – an fMRI study. Behavioural Brain Research, 2017, 324, 1-14.	2.2	53
42	Letter to Editor in Response to Johnson's Commentary (2017) on the Witkiewitz and Colleagues (2017) Article. Alcoholism: Clinical and Experimental Research, 2017, 41, 1381-1382.	2.4	5
43	Change in non-abstinent WHO drinking risk levels and alcohol dependence: a 3 year follow-up study in the US general population. Lancet Psychiatry,the, 2017, 4, 469-476.	7.4	108
44	Clinical Validation of Reduced Alcohol Consumption After Treatment for Alcohol Dependence Using the World Health Organization Risk Drinking Levels. Alcoholism: Clinical and Experimental Research, 2017, 41, 179-186.	2.4	123
45	Reduced Drinking in Alcohol Dependence Treatment, What Is the Evidence?. European Addiction Research, 2017, 23, 219-230.	2.4	67
46	Can reduced drinking be a viable goal for alcohol dependent patients?. World Psychiatry, 2017, 16, 325-326.	10.4	16
47	Gaming disorder: Its delineation as an important condition for diagnosis, management, and prevention. Journal of Behavioral Addictions, 2017, 6, 271-279.	3.7	359
48	Low μ-Opioid Receptor Status in Alcohol Dependence Identified by Combined Positron Emission Tomography and Post-Mortem Brain Analysis. Neuropsychopharmacology, 2017, 42, 606-614.	5.4	51
49	Reward and relief dimensions of temptation to drink: construct validity and role in predicting differential benefit from acamprosate and naltrexone. Addiction Biology, 2017, 22, 1528-1539.	2.6	40
50	Genetic Contribution to Alcohol Dependence: Investigation of a Heterogeneous German Sample of Individuals with Alcohol Dependence, Chronic Alcoholic Pancreatitis, and Alcohol-Related Cirrhosis. Genes, 2017, 8, 183.	2.4	11
51	The 2015 French guidelines on alcohol misuse, issued in partnership with the European Federation of Addiction Societies: a focus on children and adolescents. European Child and Adolescent Psychiatry, 2016, 25, 1145-1148.	4.7	6
52	A Pointâ€byâ€Point Response to Braillon. CNS Neuroscience and Therapeutics, 2016, 22, 537-538.	3.9	0
53	Pharmacotherapy for Alcohol Dependence: The 2015 Recommendations of the French Alcohol Society, Issued in Partnership with the European Federation of Addiction Societies. CNS Neuroscience and Therapeutics, 2016, 22, 25-37.	3.9	91
54	Structural brain correlates of adolescent resilience. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2016, 57, 1287-1296.	5. 2	49

#	Article	IF	CITATIONS
55	Analysis of Rare Variants in the Alcohol Dependence Candidate Gene GATA 4. Alcoholism: Clinical and Experimental Research, 2016, 40, 1627-1632.	2.4	1
56	Exploring the Neural Basis of Avatar Identification in Pathological Internet Gamers and of Self-Reflection in Pathological Social Network Users. Journal of Behavioral Addictions, 2016, 5, 485-499.	3.7	34
57	Prediction of alcohol drinking in adolescents: Personality-traits, behavior, brain responses, and genetic variations in the context of reward sensitivity. Biological Psychology, 2016, 118, 79-87.	2.2	49
58	Does Acamprosate Really Produce its Anti-Relapse Effects via Calcium? No Support from the PREDICT Study in Human Alcoholics. Neuropsychopharmacology, 2016, 41, 659-660.	5.4	18
59	Neural correlates of three types of negative life events during angry face processing in adolescents. Social Cognitive and Affective Neuroscience, 2016, 11, 1961-1969.	3.0	15
60	Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy. European Neuropsychopharmacology, 2016, 26, 1941-1949.	0.7	77
61	Marketing Status and Perceived Efficacy of Drugs for Supporting Abstinence and Reducing Alcohol Intake in Alcohol Use Disorders: A Survey among European Federation of Addiction Societies in Europe. European Addiction Research, 2016, 22, 318-321.	2.4	6
62	Association of the OPRM1 Variant rs1799971 (A118G) with Non-Specific Liability to Substance Dependence in a Collaborative de novo Meta-Analysis of European-Ancestry Cohorts. Behavior Genetics, 2016, 46, 151-169.	2.1	98
63	Personality and Substance Use: Psychometric Evaluation and Validation of the Substance Use Risk Profile Scale (<scp>SURPS</scp>) in English, Irish, French, and German Adolescents. Alcoholism: Clinical and Experimental Research, 2015, 39, 2234-2248.	2.4	41
64	The effects of single nucleotide polymorphisms in glutamatergic neurotransmission genes on neural response to alcohol cues and craving. Addiction Biology, 2015, 20, 1022-1032.	2.6	30
65	Robust regression for large-scale neuroimaging studies. Neurolmage, 2015, 111, 431-441.	4.2	14
66	Correlated gene expression supports synchronous activity in brain networks. Science, 2015, 348, 1241-1244.	12.6	532
67	Safety and tolerability of as-needed nalmefene in the treatment of alcohol dependence: results from the Phase III clinical programme. Expert Opinion on Drug Safety, 2015, 14, 495-504.	2.4	18
68	Avatar's neurobiological traces in the self-concept of massively multiplayer online role-playing game (MMORPG) addicts Behavioral Neuroscience, 2015, 129, 8-17.	1.2	79
69	Effects of d-cycloserine on extinction of mesolimbic cue reactivity in alcoholism: a randomized placebo-controlled trial. Psychopharmacology, 2015, 232, 2353-2362.	3.1	57
70	XRCC5 as a Risk Gene for Alcohol Dependence: Evidence from a Genome-Wide Gene-Set-Based Analysis and Follow-up Studies in Drosophila and Humans. Neuropsychopharmacology, 2015, 40, 361-371.	5.4	12
71	Reinforcement-Related Subphenotypes as a Basis for Personalized Treatment in Alcoholism. Alcoholism: Clinical and Experimental Research, 2015, 39, 589-589.	2.4	0
72	Optimized protocol for high resolution functional magnetic resonance imaging at 3T using single-shot echo planar imaging. Journal of Neuroscience Methods, 2015, 239, 170-182.	2.5	2

#	Article	IF	Citations
73	Personality, Attentional Biases towards Emotional Faces and Symptoms of Mental Disorders in an Adolescent Sample. PLoS ONE, 2015, 10, e0128271.	2.5	10
74	Predicting Naltrexone Response in Alcoholâ€Dependent Patients: The Contribution of Functional Magnetic Resonance Imaging. Alcoholism: Clinical and Experimental Research, 2014, 38, 2754-2762.	2.4	79
75	Aversive Learning in Adolescents: Modulation by Amygdala–Prefrontal and Amygdala–Hippocampal Connectivity and Neuroticism. Neuropsychopharmacology, 2014, 39, 875-884.	5.4	41
76	Sex Differences in COMT Polymorphism Effects on Prefrontal Inhibitory Control in Adolescence. Neuropsychopharmacology, 2014, 39, 2560-2569.	5.4	53
77	Global Genetic Variations Predict Brain Response to Faces. PLoS Genetics, 2014, 10, e1004523.	3.5	18
78	Predictors of Abstinence from Heavy Drinking During Treatment in <scp>COMBINE</scp> and External Validation in <scp>PREDICT</scp> . Alcoholism: Clinical and Experimental Research, 2014, 38, 2647-2656.	2.4	18
79	Insula and striatum activity in effort-related monetary reward processing in gambling disorder: The role of depressive symptomatology. Neurolmage: Clinical, 2014, 6, 243-251.	2.7	31
80	Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomised controlled study. Journal of Psychopharmacology, 2014, 28, 733-744.	4.0	109
81	Association between alcohol-cue modulated startle reactions and drinking behaviour in alcohol dependent patients — results of the PREDICT study. International Journal of Psychophysiology, 2014, 94, 263-271.	1.0	14
82	Neurobiological correlates of physical self-concept and self-identification with avatars in addicted players of Massively Multiplayer Online Role-Playing Games (MMORPGs). Addictive Behaviors, 2014, 39, 1789-1797.	3.0	92
83	Neuropsychosocial profiles of current and future adolescent alcohol misusers. Nature, 2014, 512, 185-189.	27.8	368
84	Experience of social discrimination correlates with neurometabolism: a pilot study in heroin addicts. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 197-203.	3.2	11
85	Extending the Treatment Options in Alcohol Dependence: A Randomized Controlled Study of As-Needed Nalmefene. Biological Psychiatry, 2013, 73, 706-713.	1.3	457
86	A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. European Neuropsychopharmacology, 2013, 23, 1432-1442.	0.7	359
87	Reward and relief craving tendencies in patients with alcohol use disorders: Results from the PREDICT study. Addictive Behaviors, 2013, 38, 1532-1540.	3.0	46
88	Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study. Addiction Biology, 2013, 18, 937-946.	2.6	98
89	Efficacy of As-Needed Nalmefene in Alcohol-Dependent Patients with at Least a High Drinking Risk Level: Results from a Subgroup Analysis of Two Randomized Controlled 6-Month Studies. Alcohol and Alcoholism, 2013, 48, 570-578.	1.6	293
90	Self-Concept Deficits in Massively Multiplayer Online Role-Playing Games Addiction. European Addiction Research, 2013, 19, 227-234.	2.4	45

#	Article	IF	Citations
91	The Alcohol Clinical Trials Initiative (ACTIVE): Purpose and Goals for Assessing Important and Salient Issues for Medications Development in Alcohol Use Disorders. Neuropsychopharmacology, 2012, 37, 402-411.	5.4	25
92	Translational Magnetic Resonance Spectroscopy Reveals Excessive Central Glutamate Levels During Alcohol Withdrawal in Humans and Rats. Biological Psychiatry, 2012, 71, 1015-1021.	1.3	173
93	Genomeâ€wide significant association between alcohol dependence and a variant in the <i>ADH</i> gene cluster. Addiction Biology, 2012, 17, 171-180.	2.6	154
94	Effects of Cue-Exposure Treatment on Neural Cue Reactivity in Alcohol Dependence: A Randomized Trial. Biological Psychiatry, 2011, 69, 1060-1066.	1.3	178
95	Alcohol and the Human Brain: A Systematic Review of Different Neuroimaging Methods. Alcoholism: Clinical and Experimental Research, 2011, 35, 1771-1793.	2.4	258
96	Individualised treatment in alcohol-dependent patients. European Archives of Psychiatry and Clinical Neuroscience, 2010, 260, 116-120.	3.2	62
97	Initial, habitual and compulsive alcohol use is characterized by a shift of cue processing from ventral to dorsal striatum. Addiction, 2010, 105, 1741-1749.	3.3	305
98	Avoidance of Alcohol-Related Stimuli Increases During the Early Stage of Abstinence in Alcohol-Dependent Patients. Alcohol and Alcoholism, 2009, 44, 458-463.	1.6	78
99	Genome-wide Association Study of Alcohol Dependence. Archives of General Psychiatry, 2009, 66, 773.	12.3	354
100	CLINICAL STUDY: Attentional bias in alcoholâ€dependent patients: the role of chronicity and executive functioning. Addiction Biology, 2009, 14, 194-203.	2.6	69
101	Searching for Responders to Acamprosate and Naltrexone in Alcoholism Treatment: Rationale and Design of the <i>Predict Study</i> . Alcoholism: Clinical and Experimental Research, 2009, 33, 674-683.	2.4	86
102	Acamprosate: Recent Findings and Future Research Directions. Alcoholism: Clinical and Experimental Research, 2008, 32, 1105-1110.	2.4	154
103	The German Society for Addiction Research and Addiction Treatment. Addiction, 2008, 103, 6-8.	3.3	4
104	The Startle Reflex in Alcohol-Dependent Patients: Changes after Cognitive-Behavioral Therapy and Predictive Validity for Drinking Behavior. Psychotherapy and Psychosomatics, 2007, 76, 385-390.	8.8	27
105	Topiramate for Treating Alcohol Dependence <subtitle>A Randomized Controlled Trial</subtitle> . JAMA - Journal of the American Medical Association, 2007, 298, 1641.	7.4	490
106	Blockade of Cue-induced Brain Activation of Abstinent Alcoholics by a Single Administration of Amisulpride as Measured With fMRI. Alcoholism: Clinical and Experimental Research, 2006, 30, 1349-1354.	2.4	88
107	Cue exposure in the treatment of alcohol dependence: Effects on drinking outcome, craving and selfâ€efficacy. British Journal of Clinical Psychology, 2006, 45, 515-529.	3.5	112
108	Severity of nicotine dependence modulates cue-induced brain activity in regions involved in motor preparation and imagery. Psychopharmacology, 2006, 184, 577-588.	3.1	202

#	Article	IF	Citations
109	New Developments in Alcoholism Treatment Research in Europe. Alcoholism: Clinical and Experimental Research, 2005, 29, 1127-1132.	2.4	9
110	Correlation of Stable Elevations in Striatal $\hat{1}/4$ -Opioid Receptor Availability in Detoxified Alcoholic Patients With Alcohol Craving. Archives of General Psychiatry, 2005, 62, 57.	12.3	231
111	The Efficacy of Acamprosate in the Maintenance of Abstinence in Alcoholâ€Dependent Individuals: Results of a Metaâ€Analysis. Alcoholism: Clinical and Experimental Research, 2004, 28, 51-63.	2.4	320
112	Does psychiatric comorbidity in alcohol-dependent patients affect treatment outcome?. European Archives of Psychiatry and Clinical Neuroscience, 2004, 254, 172-81.	3.2	55
113	Cue-induced activation of the striatum and medial prefrontal cortex is associated with subsequent relapse in abstinent alcoholics. Psychopharmacology, 2004, 175, 296-302.	3.1	526
114	Pharmacotherapy of Alcohol Dependence. CNS Drugs, 2004, 18, 485-504.	5.9	187
115	REWARD CRAVING AND WITHDRAWAL RELIEF CRAVING: ASSESSMENT OF DIFFERENT MOTIVATIONAL PATHWAYS TO ALCOHOL INTAKE. Alcohol and Alcoholism, 2003, 38, 35-39.	1.6	188
116	Sex Differences of Carbohydrate-Deficient Transferrin, gamma-Glutamyltransferase, and Mean Corpuscular Volume in Alcohol-Dependent Patients. Alcoholism: Clinical and Experimental Research, 2000, 24, 1400-1405.	2.4	30
117	Addressing the Associated Conditions of Drug and Alcohol Abuse. , 0, , 531-541.		1